Premium
The Effect of Arvin on Blood Coagulation Factors
Author(s) -
Bell William R.,
Bolton Gillian,
Pitney W. R.
Publication year - 1968
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1968.tb01581.x
Subject(s) - fibrinogen , chemistry , coagulation , medicine , calcium , prothrombin time , incubation , endocrinology , urea , thromboplastin , in vitro , biochemistry
The effect of Arvin on blood coagulation factors was studied both in vitro and in patients undergoing therapeutic defibrination. Clots produced in citrated or EDTA plasma were soluble in 5 M urea, but rendered insoluble by prior incubation with calcium. Clots produced in heparinized plasma were urea‐soluble, even in the presence of excess calcium ions. An apparent increase in the prothrombin concentration of defibrinated plasma was related to the method of prothrombin assay. There was no significant reduction in the concentration of Factors V, VIII, IX and X, but some loss of Factor VII in plasma samples defibrinated with Arvin in vitro. The stability on storage of Factor VIII in plasma defibrinated in vitro was similar to that in control plasma samples. When Arvin was administered to patients, there was a rapid fall in plasma fibrinogen concentrations, which could be maintained at levels below 50 mg. per 100 ml. by twice daily injections. Following cessation of therapy, plasma fibrinogen concentrations increased slowly and did not reach normal values until 2–3 weeks later. The administration of antivenene in the first 3 days following cessation of Arvin therapy did not affect this slow return to normal values. There was no significant reduction in other coagulation factors during therapeutic defibrination.